While this collaboration does not bring immediate revenue, it significantly de-risks muzastotug’s platform potential and could lead to future partnerships or licensing deals. Traders should monitor enrollment initiation in 2026 and any interim data readouts from the combination study, especially in liver-metastatic MSS CRC, a population with high unmet need.
Price Chart
Executive Summary
Adagene announced a clinical collaboration with Incyte to evaluate its masked anti-CTLA-4 therapy muzastotug in combination with Incyte's TGFβR2 × PD-1 bispecific INCA33890 in microsatellite stable colorectal cancer (MSS CRC) patients, with a Phase 1 study expected to begin in 2026. This marks the second major validation of Adagene’s SAFEbody technology in a PD-1–based combination, reinforcing its potential as a backbone immunotherapy. The study will focus on a high-need population—MSS CRC patients with liver metastases—who have limited treatment options and poor prognosis.
Key Facts
- Adagene and Incyte are collaborating on a Phase 1 study combining muzastotug (ADG126) and INCA33890 in 3L MSS CRC patients, with or without liver metastases.
- Study expected to begin in 2026; Incyte will sponsor and conduct the trial, Adagene will supply muzastotug.
- Muzastotug has FDA Fast Track designation and is based on Adagene’s SAFEbody® precision masking technology.
- This is the second major collaboration validating muzastotug as a backbone therapy in next-gen immuno-oncology combinations.
- Incyte is already running a Phase 3 trial of INCA33890 in 1L MSS CRC (NCT07284849), suggesting strong confidence in the molecule.
Financial Impact
Non-dilutive validation with potential future milestone and royalty upside; no upfront payment disclosed.
Risk Factors
- Clinical development timelines are long; Phase 1 data not expected until 2027–2028.
- Combination therapy may not show improved efficacy or safety over monotherapies.
- Adagene remains clinical-stage with no commercial products, dependent on partnership and trial outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267231 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $3.20 | awaiting T+60 | — | $2.49 (−22.19%) |
Sep 22, 2026 4w ago | 6-K | $3.23 | awaiting T+60 | — | $2.49 (−22.91%) |
Sep 10, 2026 6w ago | 6-K | $3.31 | awaiting T+60 | — | $2.49 (−24.77%) |
Sep 9, 2026 6w ago | 6-K | $3.27 | awaiting T+60 | — | $2.49 (−23.85%) |
Aug 16, 2026 10w ago | Institutional Cluster | $3.83 | awaiting T+60 | — | $2.49 (−34.99%) |
Aug 12, 2026 10w ago | 6-K | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Aug 12, 2026 10w ago | Press Release | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Jul 6, 2026 16w ago | 6-K | $3.93 $3.21 | ▼ −18.32% | ▼ −20.04% | $2.49 (−36.64%) |
Apr 17, 2026 27w ago | 6-K | $3.89 $3.67 | ▼ −5.66% | ▼ −12.43% | $2.49 (−35.99%) |
Apr 2, 2026 29w ago | 6-K | $3.99 $4.20 | ▼ −5.26% | ▲ +8.90% | $2.49 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers